Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $143.40.

Several equities research analysts recently commented on MIRM shares. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Evercore reissued an “outperform” rating and issued a $138.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Royal Bank Of Canada lifted their target price on Mirum Pharmaceuticals from $142.00 to $148.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This trade represents a 13.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total transaction of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares in the company, valued at $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,315 shares of company stock valued at $6,991,928 in the last quarter. 8.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Janus Henderson Group PLC boosted its stake in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after buying an additional 880,505 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Mirum Pharmaceuticals by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after acquiring an additional 50,720 shares in the last quarter. State Street Corp increased its position in shares of Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after acquiring an additional 797,088 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Mirum Pharmaceuticals by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock valued at $112,196,000 after acquiring an additional 137,087 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in Mirum Pharmaceuticals by 56.6% during the fourth quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after acquiring an additional 447,141 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM opened at $122.13 on Monday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of -8.97 and a beta of 0.48. The business has a 50 day simple moving average of $106.49 and a 200 day simple moving average of $97.84. Mirum Pharmaceuticals has a 52-week low of $50.25 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) EPS. Analysts anticipate that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.